JENNIFERLITTONJENNIFER LITTON9234LITTON, JENNIFERAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson19460581Anders CK, Johnson R, Litton J, Phillips M, Bleyer ASeminars in oncologyBreast cancer before age 40 years. Semin Oncol. 2009 Jun; 36(3):237-49.Semin Oncol2009-06-01T00:00:002009Breast cancer before age 40 years.25224030Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JKCancerCancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer. 2015 Jan 15; 121(2):269-75.Cancer2014-09-15T00:00:002014Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.25547133Murthy RK, Theriault RL, Barnett CM, Hodge S, Ramirez MM, Milbourne A, Rimes SA, Hortobagyi GN, Valero V, Litton JKBreast cancer research : BCROutcomes of children exposed in utero to chemotherapy for breast cancer. Breast Cancer Res. 2014 Dec 30; 16(6):500.Breast Cancer Res2014-12-30T00:00:002014Outcomes of children exposed in utero to chemotherapy for breast cancer.1155 Pressler StHouston77030-3721TXAuthorship 1805841Authorship 1816753Authorship 1838562Authorship 1841272Authorship 18428211Authorship 18495311Authorship 1853858Authorship 1872473Authorship 1879452Authorship 1889623Authorship 1891896Authorship 1894829Authorship 1903101Authorship 1903335Authorship 1910071Authorship 1921752Authorship 1924423Authorship 1932355Authorship 193951119884543Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GNJournal of clinical oncology : official journal of the American Society of Clinical OncologyHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009 Dec 01; 27(34):5700-6.J Clin Oncol2009-11-02T00:00:002009High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.20647335Yi M, Hunt KK, Arun BK, Bedrosian I, Barrera AG, Do KA, Kuerer HM, Babiera GV, Mittendorf EA, Ready K, Litton J, Meric-Bernstam FCancer prevention research (Philadelphia, Pa.)Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010 Aug; 3(8):1026-34.Cancer Prev Res (Phila)2010-07-20T00:00:002010Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy.22009639Bayraktar S, Elsayegh N, Gutierrez Barrera AM, Lin H, Kuerer H, Tasbas T, Muse KI, Ready K, Litton J, Meric-Bernstam F, Hortobagyi GN, Albarracin CT, Arun BCancerPredictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer. 2012 Mar 15; 118(6):1515-22.Cancer2011-08-25T00:00:002011Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.22359359Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AMCancerIncidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer. Cancer. 2012 Oct 01; 118(19):4652-9.Cancer2012-02-22T00:00:002012Incidence of brain metastases as a first site of recurrence among women with triple receptor-negative breast cancer.22621334Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EABreast cancer research : BCRLocal-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012 May 23; 14(3):R83.Breast Cancer Res2012-05-23T00:00:002012Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.23109691Litton JK, Gonzalez-Angulo AMJournal of clinical oncology : official journal of the American Society of Clinical OncologyEvaluating breast cancer risk with genome-wide association studies: is this approach patient ready? J Clin Oncol. 2012 Dec 10; 30(35):4288-9.J Clin Oncol2012-10-29T00:00:002012Evaluating breast cancer risk with genome-wide association studies: is this approach patient ready?23231005Meric-Bernstam F, Gutierrez-Barrera AM, Litton J, Mellor-Crummey L, Ready K, Gonzalez-Angulo AM, Lu KH, Hortobagyi GN, Arun BKThe breast journalGenotype in BRCA-associated breast cancers. Breast J. 2013 Jan-Feb; 19(1):87-91.Breast J2012-12-10T00:00:002012Genotype in BRCA-associated breast cancers.23337751Bayraktar S, Gutierrez Barrera AM, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun BCancer journal (Sudbury, Mass.)USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J. 2013 Jan-Feb; 19(1):10-7.Cancer J2013-01-01T00:00:002013USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer.23769223Litton J, Buzdar A, Mac Gregor MC, Gonzalez-Angulo A, Hortobagyi GLancet (London, England)Tamoxifen therapy for patients with breast cancer. Lancet. 2013 Jun 15; 381(9883):2077-8.Lancet2013-06-15T00:00:002013Tamoxifen therapy for patients with breast cancer.Breast Medical OncologyDiagnostic RadiologyInvestigational Cancer TherapeuticsStem Cell TransplantationMD AndersonHENRY MARKKUERERHENRY MARK KUERER8727KUERER, HENRY MARKProfessorBEATRIZ ELENAADRADABEATRIZ ELENA ADRADA9421ADRADA, BEATRIZ ELENAAssociate ProfessorGAIANE MARGISHVILIRAUCHGAIANE MARGISHVILI RAUCH9511RAUCH, GAIANE MARGISHVILIAssociate ProfessorKELLY KHUNTKELLY K HUNT8555HUNT, KELLY KProfessorELIZABETH ANNMITTENDORFELIZABETH ANN MITTENDORF9277MITTENDORF, ELIZABETH ANNAssociate ProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorBANU KARUNBANU K ARUN8898ARUN, BANU KProfessor5.107440.0115308388research areas7.460380.0230425155coauthor of184.34330.187860similar to11210selected publicationsAuthorship 2246101Authorship 2254996Authorship 22862812Authorship 2288257Authorship 2296537Authorship 22994110Authorship 2304827Authorship 2305031Authorship 2310454Authorship 2311546Authorship 2312321Authorship 2317471Authorship 23238411Authorship 2336545Authorship 23430810Authorship 2344371Authorship 234774617676585Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun BCancerMultifocal breast cancer in women < or =35 years old. Cancer. 2007 Oct 01; 110(7):1445-50.Cancer2007-10-01T00:00:002007Multifocal breast cancer in women < or =35 years old.19204903Beadle BM, Woodward WA, Middleton LP, Tereffe W, Strom EA, Litton JK, Meric-Bernstam F, Theriault RL, Buchholz TA, Perkins GHCancerThe impact of pregnancy on breast cancer outcomes in women<or=35 years. Cancer. 2009 Mar 15; 115(6):1174-84.Cancer2009-03-15T00:00:002009The impact of pregnancy on breast cancer outcomes in women<or=35 years.21147692Valero V, Kong AL, Hunt KK, Yi M, Hwang RF, Meric-Bernstam F, Bedrosian I, Ross MI, Babiera GV, Litton JK, Mittendorf EAClinical breast cancerSentinel lymph node dissection is technically feasible in older breast cancer patients. Clin Breast Cancer. 2010 Dec 01; 10(6):477-82.Clin Breast Cancer2010-12-01T00:00:002010Sentinel lymph node dissection is technically feasible in older breast cancer patients.21327455Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EAAnnals of surgical oncologyMultidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.Ann Surg Oncol2011-09-01T00:00:002011Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial.21365619Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BKCancerEffectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011 Sep 01; 117(17):3900-7.Cancer2011-03-01T00:00:002011Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.21590688Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AMCancerBisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer. 2012 Jan 15; 118(2):326-32.Cancer2011-05-16T00:00:002011Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.21761402Melhem-Bertrandt A, Bojadzieva J, Ready KJ, Obeid E, Liu DD, Gutierrez-Barrera AM, Litton JK, Olopade OI, Hortobagyi GN, Strong LC, Arun BKCancerEarly onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012 Feb 15; 118(4):908-13.Cancer2011-07-14T00:00:002011Early onset HER2-positive breast cancer is associated with germline TP53 mutations.21830012Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, Lin E, Albarracin CT, Meric-Bernstam F, Gonzalez-Angulo AM, Hortobagyi GN, Arun BKBreast cancer research and treatmentOutcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011 Nov; 130(1):145-53.Breast Cancer Res Treat2011-08-10T00:00:002011Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.21900106Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin CJournal of clinical oncology : official journal of the American Society of Clinical OncologyResponse to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011 Oct 01; 29(28):3739-46.J Clin Oncol2011-09-06T00:00:002011Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.21913181Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, Gonzalez-Angulo AM, Le-Petross H, Lu K, Hortobagyi GN, Arun BKCancerEarlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer. 2012 Jan 15; 118(2):321-5.Cancer2011-09-12T00:00:002011Earlier age of onset of BRCA mutation-related cancers in subsequent generations.22392043Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KKBreast cancer research and treatmentBiologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass. Breast Cancer Res Treat. 2012 Jun; 133(3):1131-41.Breast Cancer Res Treat2012-03-04T00:00:002012Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass.22396154Litton JKCurrent treatment options in oncologyBreast cancer and fertility. Curr Treat Options Oncol. 2012 Jun; 13(2):137-45.Curr Treat Options Oncol2012-06-01T00:00:002012Breast cancer and fertility.22531361Keating Litton JThe oncologistIs age still the deciding factor? Commentary on "The effect of age on delay in diagnosis and stage of breast cancer" by Partridge et al. Oncologist. 2012; 17(6):744-6.Oncologist2012-04-24T00:00:002012Is age still the deciding factor? Commentary on "The effect of age on delay in diagnosis and stage of breast cancer" by Partridge et al.22903527Del Fabbro E, Parsons H, Warneke CL, Pulivarthi K, Litton JK, Dev R, Palla SL, Brewster A, Bruera EThe oncologistThe relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist. 2012; 17(10):1240-5.Oncologist2012-08-17T00:00:002012The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer.23576478Litton JK, Warneke CL, Hahn KM, Palla SL, Kuerer HM, Perkins GH, Mittendorf EA, Barnett C, Gonzalez-Angulo AM, Hortob?gyi GN, Theriault RLThe oncologistCase control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist. 2013; 18(4):369-76.Oncologist2013-04-10T00:00:002013Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.23983819Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-Macgregor MJournal of CancerUse of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. J Cancer. 2013; 4(7):549-56.J Cancer2013-08-10T00:00:002013Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes.24522996Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG, Northwestern Cancer Genetics GroupCancerCharacteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64.Cancer2014-02-12T00:00:002014Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2.Authorship 25214512Authorship 2528992Authorship 25528614Authorship 2560915Authorship 2564604Authorship 2566542Authorship 2592072Authorship 2597334Authorship 26016711Authorship 261536218707822Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TAInternational journal of radiation oncology, biology, physicsTen-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009 Mar 01; 73(3):734-44.Int J Radiat Oncol Biol Phys2008-08-15T00:00:002008Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.20222793Ready K, Litton JK, Arun BKFuture oncology (London, England)Clinical application of breast cancer risk assessment models. Future Oncol. 2010 Mar; 6(3):355-65.Future Oncol2010-03-01T00:00:002010Clinical application of breast cancer risk assessment models.20495085Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN, National Comprehensive Cancer NetworkJournal of the National Comprehensive Cancer Network : JNCCNGenetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2010 May; 8(5):562-94.J Natl Compr Canc Netw2010-05-01T00:00:002010Genetic/familial high-risk assessment: breast and ovarian.20665886Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai LCancerUtility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer. 2010 Nov 15; 116(22):5161-7.Cancer2010-11-15T00:00:002010Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.21233401Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchIncidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.Clin Cancer Res2011-01-13T00:00:002011Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.21764391Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AMClinical breast cancerAge and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer. 2011 Oct; 11(5):325-31.Clin Breast Cancer2011-07-20T00:00:002011Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype.23720073Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EAAnnals of surgical oncologyOutcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy. Ann Surg Oncol. 2013 Oct; 20(11):3430-7.Ann Surg Oncol2013-05-30T00:00:002013Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy.23733755Theriault RL, Litton JKJournal of clinical oncology : official journal of the American Society of Clinical OncologyPregnancy during or after breast cancer diagnosis: what do we know and what do we need to know? J Clin Oncol. 2013 Jul 10; 31(20):2521-2.J Clin Oncol2013-06-03T00:00:002013Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?24297948Theriault RL, Litton JKJournal of clinical oncology : official journal of the American Society of Clinical OncologyReply to D. Crivellari et al. J Clin Oncol. 2014 Jan 20; 32(3):256-7.J Clin Oncol2013-12-02T00:00:002013Reply to D. Crivellari et al.24461458Morrow PK, Broxson AC, Munsell MF, Basen-Enquist K, Rosenblum CK, Schover LR, Nguyen LH, Hsu L, Castillo L, Hahn KM, Litton JK, Kwiatkowski DN, Hortobagyi GNClinical breast cancerEffect of age and race on quality of life in young breast cancer survivors. Clin Breast Cancer. 2014 Apr; 14(2):e21-31.Clin Breast Cancer2013-10-25T00:00:002013Effect of age and race on quality of life in young breast cancer survivors.Authorship 2681015Authorship 2693781Authorship 2697381Authorship 2699885Authorship 2703281Authorship 2718078Authorship 2718961618581139Eralp Y, Smith TL, Altundag K, Kau SW, Litton J, Valero V, Buzdar A, Hortobagyi GN, Arun BJournal of cancer research and clinical oncologyClinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.J Cancer Res Clin Oncol2008-06-26T00:00:002008Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger.19280625Litton JK, Westin SN, Ready K, Sun CC, Peterson SK, Meric-Bernstam F, Gonzalez-Angulo AM, Bodurka DC, Lu KH, Hortobagyi GN, Arun BKCancerPerception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. Cancer. 2009 Apr 15; 115(8):1598-604.Cancer2009-04-15T00:00:002009Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation.21147871Litton JK, Theriault RLThe oncologistBreast cancer and pregnancy: current concepts in diagnosis and treatment. Oncologist. 2010; 15(12):1238-47.Oncologist2010-12-08T00:00:002010Breast cancer and pregnancy: current concepts in diagnosis and treatment.21800293Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AMCancerEffect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012 Mar 01; 118(5):1202-11.Cancer2011-07-28T00:00:002011Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.22590484Litton JK, Bevers TB, Arun BKTherapeutic advances in medical oncologyExemestane in the prevention setting. Ther Adv Med Oncol. 2012 May; 4(3):107-12.Ther Adv Med Oncol2012-05-01T00:00:002012Exemestane in the prevention setting.23897970Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera EJournal of clinical oncology : official journal of the American Society of Clinical OncologyReduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013 Sep 01; 31(25):3076-82.J Clin Oncol2013-07-29T00:00:002013Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.24742739Andr? F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni LThe Lancet. OncologyEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014 May; 15(6):580-91.Lancet Oncol2014-04-14T00:00:002014Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.Authorship 2737841Authorship 2745076Authorship 2749633Authorship 2749924Authorship 2754401519392610Litton JK, Theriault RL, Gonzalez-Angulo AMWomen's health (London, England)Breast cancer diagnosis during pregnancy. Womens Health (Lond). 2009 May; 5(3):243-9.Womens Health (Lond)2009-05-01T00:00:002009Breast cancer diagnosis during pregnancy.21947595Adkins FC, Gonzalez-Angulo AM, Lei X, Hernandez-Aya LF, Mittendorf EA, Litton JK, Wagner J, Hunt KK, Woodward WA, Meric-Bernstam FAnnals of surgical oncologyTriple-negative breast cancer is not a contraindication for breast conservation. Ann Surg Oncol. 2011 Oct; 18(11):3164-73.Ann Surg Oncol2011-09-27T00:00:002011Triple-negative breast cancer is not a contraindication for breast conservation.23040004Dawood S, Lei X, Litton JK, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AMClinical breast cancerImpact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer. 2012 Oct; 12(5):364-72.Clin Breast Cancer2012-10-01T00:00:002012Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer.23819023Woodson AH, Profato JL, Muse KI, Litton JKJournal of thoracic diseaseBreast cancer in the young: role of the geneticist. J Thorac Dis. 2013 Jun; 5 Suppl 1:S19-26.J Thorac Dis2013-06-01T00:00:002013Breast cancer in the young: role of the geneticist.24764583Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, Alatrash GCancer immunology researchPD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014 Apr; 2(4):361-70.Cancer Immunol Res2014-01-10T00:00:002014PD-L1 expression in triple-negative breast cancer.Authorship 27897810Authorship 27907213Authorship 27916314Authorship 2797438Authorship 2893587Authorship 29161713Authorship 2925256Authorship 2928473Authorship 2947479Authorship 2948238Authorship 2988576Authorship 3018373Authorship 3030864Authorship 3031879Authorship 3033589Authorship 3037531Authorship 304215724796968Elsayegh N, Kuerer HM, Lin H, Gutierrez Barrera AM, Jackson M, Muse KI, Litton JK, Albarracin C, Afrough A, Hortobagyi GN, Arun BKAnnals of surgical oncologyPredictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing. Ann Surg Oncol. 2014 Oct; 21(11):3466-72.Ann Surg Oncol2014-05-06T00:00:002014Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.25190698Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R, National comprehensive cancer networkJournal of the National Comprehensive Cancer Network : JNCCNGenetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014 Sep; 12(9):1326-38.J Natl Compr Canc Netw2014-09-01T00:00:002014Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.25381882Rich TA, Woodson AH, Litton J, Arun BJournal of surgical oncologyHereditary breast cancer syndromes and genetic testing. J Surg Oncol. 2015 Jan; 111(1):66-80.J Surg Oncol2014-11-07T00:00:002014Hereditary breast cancer syndromes and genetic testing.25454687Parinyanitikul N, Lei X, Chavez-MacGregor M, Liu S, Mittendorf EA, Litton JK, Woodward W, Zhang AH, Hortobagyi GN, Valero V, Meric-Bernstam F, Gonzalez-Angulo AMClinical breast cancerReceptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. Clin Breast Cancer. 2015 Apr; 15(2):153-60.Clin Breast Cancer2014-10-02T00:00:002014Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes.25767600Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NTJournal of CancerAssociation of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. J Cancer. 2015; 6(4):310-8.J Cancer2015-01-22T00:00:002015Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.25789811Bayraktar S, Jackson M, Gutierrez-Barrera AM, Liu D, Meric-Bernstam F, Brandt A, Woodson A, Litton J, Lu KH, Valero V, Arun BKThe breast journalGenotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers. Breast J. 2015 May-Jun; 21(3):260-7.Breast J2015-03-19T00:00:002015Genotype-Phenotype Correlations by Ethnicity and Mutation Location in BRCA Mutation Carriers.25913905Gonzalez-Angulo AM, Lei X, Alvarez RH, Green MC, Murray JL, Valero V, Koenig KB, Ibrahim NK, Litton JK, Nair L, Krishnamurthy S, Hortobagyi GN, Meric-Bernstam FClinical breast cancerPhase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31.Clin Breast Cancer2015-03-24T00:00:002015Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.25948675Mitri ZI, Jackson M, Garby C, Song J, Giordano SH, Hortob?gyi GN, Singletary CN, Hashmi SS, Arun BK, Litton JKThe oncologistBRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. Oncologist. 2015 Jun; 20(6):593-7.Oncologist2015-05-06T00:00:002015BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.25973541Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NTOncotargetIs the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908.Oncotarget2015-05-30T00:00:002015Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?26018033Litton JK, Lee JH, Arun BKCancerReply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer. 2015 Sep 01; 121(17):3047.Cancer2015-05-27T00:00:002015Reply to BRCA2-associated pancreatic cancer and current screening guidelines.26078790Elsayegh N, Profato J, Barrera AM, Lin H, Kuerer HM, Ardic C, Litton JK, Tripathy D, Arun BKJournal of CancerPredictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative. J Cancer. 2015; 6(7):610-5.J Cancer2015-05-23T00:00:002015Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative.26280679Sanford RA, Song J, Gutierrez-Barrera AM, Profato J, Woodson A, Litton JK, Bedrosian I, Albarracin CT, Valero V, Arun BCancerHigh incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors. Cancer. 2015 Oct 01; 121(19):3422-7.Cancer2015-08-17T00:00:002015High incidence of germline BRCA mutation in patients with ER low-positive/PR low-positive/HER-2 neu negative tumors.26706041Kehl KL, Shen C, Litton JK, Arun B, Giordano SHBreast cancer research and treatmentRates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 Jan; 155(1):165-73.Breast Cancer Res Treat2015-12-26T00:00:002015Rates of BRCA1/2 mutation testing among young survivors of breast cancer.74Professor54Instructor14Associate ProfessorBreast Surgical OncologyHAVEN REBECCAGARBERHAVEN REBECCA GARBER11878GARBER, HAVEN REBECCAInstructor26511263Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EAAnnals of surgical oncologyLocoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol. 2016 Mar; 23(3):749-56.Ann Surg Oncol2015-10-28T00:00:002015Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.20519803Dominici LS, Kuerer HM, Babiera G, Hahn KM, Perkins G, Middleton L, Ramirez MM, Yang W, Hortobagyi GN, Theriault RL, Litton JKBreast diseaseWound complications from surgery in pregnancy-associated breast cancer (PABC). Breast Dis. 2010; 31(1):1-5.Breast Dis2010-01-01T00:00:002010Wound complications from surgery in pregnancy-associated breast cancer (PABC).20133259Silberfein EJ, Hunt KK, Broglio K, Shen J, Sahin A, Le-Petross H, Oh J, Litton J, Hwang RF, Mittendorf EAClinical breast cancerClinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma. Clin Breast Cancer. 2010 Feb; 10(1):52-8.Clin Breast Cancer2010-02-01T00:00:002010Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma.21761336Chen JQ, Bao Y, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Katz RL, Sahin A, Bondy M, Murray JL, Radvanyi LHormones & cancerExpression and relevance of TRPS-1: a new GATA transcription factor in breast cancer. Horm Cancer. 2011 Apr; 2(2):132-43.Horm Cancer2011-04-01T00:00:002011Expression and relevance of TRPS-1: a new GATA transcription factor in breast cancer.21532405Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HMPlastic and reconstructive surgeryManagement of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg. 2011 May; 127(5):1763-1772.Plast Reconstr Surg2011-05-01T00:00:002011Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy.Authorship 841674Authorship 841976Authorship 843495Authorship 844007Authorship 847281Authorship 847358Authorship 848155Authorship 848472Authorship 848614Authorship 850556Authorship 851650Authorship 851797Authorship 852019Authorship 852158Authorship 852396Authorship 852957Authorship 853450Authorship 853526Authorship 854211Authorship 855104Authorship 855215Authorship 856055Authorship 856240Authorship 856683Authorship 858597Authorship 859024Authorship 859030Authorship 859676Authorship 860178Authorship 860414Authorship 860721Authorship 862391Authorship 862956Authorship 863135Authorship 863157Authorship 863606Authorship 864377Authorship 865003Authorship 865778OncotargetIs the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 6:12890-12908.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?OncotargetPrimary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 7:66192-66201.Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrenceJournal of CancerPredictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negative. Journal of Cancer. 6:610-615.Predictors that influence election of contralateral prophylactic mastectomy among women with ductal carcinoma in situ who are BRCA-negativeBreast DiseasesSafety of pregnancy following breast cancer diagnosis. Breast Diseases. 22:125-127.Safety of pregnancy following breast cancer diagnosisBreast JournalErratum. Breast Journal. 19:460.ErratumBreast DiseasesBreast cancer presentation and diagnostic delays in young women. Breast Diseases. 25:210-211.Breast cancer presentation and diagnostic delays in young womenBreast DiseasesIncidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy. Breast Diseases. 24:140-141.Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancyBreast DiseasesBreast cancer in pregnancy. Breast Diseases. 22:130-131.Breast cancer in pregnancyJNCCN Journal of the National Comprehensive Cancer NetworkGenetic/familial high-risk assessment. JNCCN Journal of the National Comprehensive Cancer Network. 14:153-162.Genetic/familial high-risk assessmentBreast DiseasesPregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Breast Diseases. 27:29-30.Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcomeCurrent Breast Cancer ReportsCurrent Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast Cancer. Current Breast Cancer Reports. 8:165-174.Current Approach to Breast Cancer Risk Reduction for Women with Hereditary Predispositions to Breast CancerJournal of Clinical OncologyTo the editor. Journal of Clinical Oncology. 27:830-831.To the editorClinical Breast CancerPhase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15:325-331.Phase II Randomized Study of Ixabepilone Versus Observation in Patients with Significant Residual Disease after Neoadjuvant Systemic Therapy for HER2-Negative Breast CancerBreast DiseasesOutcome of small invasive breast cancer with no axillary lymph node involvement. Breast Diseases. 22:272-273.Outcome of small invasive breast cancer with no axillary lymph node involvementBreast Cancer Research and TreatmentRates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Research and Treatment. 155:165-173.Rates of BRCA1/2 mutation testing among young survivors of breast cancerBreast DiseasesPredictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Diseases. 23:140-141.Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriersCancerErratum. Cancer. 118:2561.ErratumBreast cancer during pregnancy and subsequent pregnancy in breast cancer survivors. Breast cancer during pregnancy and subsequent pregnancy in breast cancer survivorsCancerErratum. Cancer. 120:927.ErratumJournal of CancerAssociation of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancer. Journal of Cancer. 6:310-318.Association of body mass index changes during neoadjuvant chemotherapy with pathologic complete response and clinical outcomes in patients with locally advanced breast cancerCancerErratum. Cancer. 121:2474-2475.ErratumAnnals of OncologyPrimary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Annals of Oncology. 27:1241-1248.Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceAnnals of Surgical OncologyLocoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Annals of Surgical Oncology. 23:749-756.Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving TherapyCancerReply to BRCA2-associated pancreatic cancer and current screening guidelines. Cancer. Reply to BRCA2-associated pancreatic cancer and current screening guidelinesBreast DiseasesExemestane for breast-cancer prevention in postmenopausal women. Breast Diseases. 23:226-227.Exemestane for breast-cancer prevention in postmenopausal womenOncotargetClinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.Clinical outcomes based on multigene profiling in metastatic breast cancer patientsOncologistBRCAPRO 6.0 model validation in male patients presenting for BRCA testing. Oncologist. 20:593-597.BRCAPRO 6.0 model validation in male patients presenting for BRCA testingBreast Cancer Research and TreatmentErratum to. Breast Cancer Research and Treatment. 1.Erratum toBreast DiseasesAge at diagnosis and distant metastasis in breast cancer - A surprising inverse relationship. Breast Diseases. 26:222-223.Age at diagnosis and distant metastasis in breast cancer - A surprising inverse relationshipOncologistCancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriers. Oncologist. 21:869-874.Cancer incidence in first- and second-degree relatives of BRCA1 and BRCA2 mutation carriersSystemic treatment during pregnancy. 765-775.Systemic treatment during pregnancyONCOLOGY (United States)Fertility preservation in women with breast cancer. ONCOLOGY (United States). 27.Fertility preservation in women with breast cancerBreast Cancer Research and TreatmentPhase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158:67-77.Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancerAnnals of OncologyIncidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology. 27:795-800.Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolCancerErratum. Cancer. 118:2997.ErratumAnnals of Surgical OncologyNomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Annals of Surgical Oncology. 1-9.Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast CancerJNCCN Journal of the National Comprehensive Cancer NetworkGenetic/familial high-risk assessment. JNCCN Journal of the National Comprehensive Cancer Network. 15:9-20.Genetic/familial high-risk assessmentFrontiers in GeneticsEvaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testing. Frontiers in Genetics. 7.Evaluation of BRCAPRO risk assessment model in patients with ductal carcinoma in situ who underwent clinical BRCA genetic testingBreast JournalGenotype-phenotype correlations by ethnicity and mutation location in brca mutation carriers. Breast Journal. 21:260-267.Genotype-phenotype correlations by ethnicity and mutation location in brca mutation carriers18757321Litton JK, Gonzalez-Angulo AM, Warneke CL, Buzdar AU, Kau SW, Bondy M, Mahabir S, Hortobagyi GN, Brewster AMJournal of clinical oncology : official journal of the American Society of Clinical OncologyRelationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008 Sep 01; 26(25):4072-7.J Clin Oncol2008-09-01T00:00:002008Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer.20564153Chavez-Macgregor M, Litton J, Chen H, Giordano SH, Hudis CA, Wolff AC, Valero V, Hortobagyi GN, Bondy ML, Gonzalez-Angulo AMCancerPathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010 Sep 01; 116(17):4168-77.Cancer2010-09-01T00:00:002010Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity.21761348Chen JQ, Litton J, Xiao L, Zhang HZ, Warneke CL, Wu Y, Shen X, Wu S, Sahin A, Katz R, Bondy M, Hortobagyi G, Berinstein NL, Murray JL, Radvanyi LHormones & cancerQuantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer. Horm Cancer. 2010 Feb; 1(1):21-33.Horm Cancer2010-02-13T00:00:002010Quantitative immunohistochemical analysis and prognostic significance of TRPS-1, a new GATA transcription factor family member, in breast cancer.22242911Litton JK, Arun BK, Brown PH, Hortobagyi GNExpert opinion on pharmacotherapyAromatase inhibitors and breast cancer prevention. Expert Opin Pharmacother. 2012 Feb; 13(3):325-31.Expert Opin Pharmacother2012-01-14T00:00:002012Aromatase inhibitors and breast cancer prevention.Authorship 8873606D019398Genes & Molecular Sequences1333860.798731Genes, BRCA1D001943Disorders1430156220.176287Breast NeoplasmsD024522Genes & Molecular Sequences1083080.821333Genes, BRCA2Authorship 9053138Authorship 90690512Authorship 9070343Authorship 9071497Authorship 9074954Authorship 9100393Authorship 91225713Authorship 91339115Authorship 9138185Authorship 9150193Authorship 9153626Authorship 9163606Authorship 9189777Authorship 91914512Authorship 9193565Authorship 92119111Authorship 9214622Authorship 92152911Authorship 9220043Authorship 92226415Authorship 9238239Authorship 9242266Authorship 92544812Authorship 9278148Authorship 93021420Authorship 93247010Authorship 9343721Authorship 9349532Authorship 935247726850485Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow SJournal of the National Comprehensive Cancer Network : JNCCNGenetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016 02; 14(2):153-62.J Natl Compr Canc Netw2016-02-01T00:00:002016Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.27306910Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, Arun BK, Litton JKThe oncologistCancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. Oncologist. 2016 07; 21(7):869-74.Oncologist2016-06-15T00:00:002016Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.27464794Kehl KL, Shen C, Litton JK, Arun B, Giordano SHBreast cancer research and treatmentErratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016 08; 159(1):201.Breast Cancer Res Treat2016-08-01T00:00:002016Erratum to: Rates of BRCA1/2 mutation testing among young survivors of breast cancer.27287781Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige NBreast cancer research and treatmentPhase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat. 2016 07; 158(1):67-77.Breast Cancer Res Treat2016-06-10T00:00:002016Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.27200080Elsayegh N, Barrera AM, Muse KI, Lin H, Kuerer HM, Helm M, Litton JK, Arun BKFrontiers in geneticsEvaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing. Front Genet. 2016; 7:71.Front Genet2016-04-27T00:00:002016Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing.27589688Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GEOncotargetPrimary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016 Oct 04; 7(40):66192-66201.Oncotarget2016-10-04T00:00:002016Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.27806348Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam FOncotargetClinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.Oncotarget2016-11-22T00:00:002016Clinical outcomes based on multigene profiling in metastatic breast cancer patients.27893038Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, Hong D, Subbiah V, Kurzrock R, Janku F, Moulder SLJAMA oncologyTargeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.JAMA Oncol2017-04-01T00:00:002017Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.28040716Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Merajver SD, Offit K, Pal T, Reiser G, Shannon KM, Swisher E, Vinayak S, Voian NC, Weitzel JN, Wick MJ, Wiesner GL, Dwyer M, Darlow SJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017 01; 15(1):9-20.J Natl Compr Canc Netw2017-01-01T00:00:002017NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.28315060Clifton GT, Litton JK, Arrington K, Ponniah S, Ibrahim NK, Gall V, Alatrash G, Peoples GE, Mittendorf EAAnnals of surgical oncologyResults of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients. Ann Surg Oncol. 2017 Aug; 24(8):2161-2167.Ann Surg Oncol2017-03-17T00:00:002017Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+?T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.28596260Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels MJournal of the National Comprehensive Cancer Network : JNCCNEvaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. J Natl Compr Canc Netw. 2017 06; 15(6):797-803.J Natl Compr Canc Netw2017-06-01T00:00:002017Evaluating the NCCN Clinical Criteria for Recommending BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.28314691Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JKThe Lancet. OncologyPrevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662.Lancet Oncol2017-03-15T00:00:002017Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial.28469042Parkes A, Arun BK, Litton JKThe oncologistSystemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. Oncologist. 2017 06; 22(6):655-666.Oncologist2017-05-03T00:00:002017Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes.28167507Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MCClinical cancer research : an official journal of the American Association for Cancer ResearchPARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017 Jul 15; 23(14):3711-3720.Clin Cancer Res2017-02-06T00:00:002017PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.29180466Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi KCancer researchSynthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018 02 01; 78(3):742-757.Cancer Res2017-11-27T00:00:002017Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.29044548Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BKCancerBRCA mutations in women with inflammatory breast cancer. Cancer. 2018 02 01; 124(3):466-474.Cancer2017-10-17T00:00:002017BRCA mutations in women with inflammatory breast cancer.29093017Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchA Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.Clin Cancer Res2017-11-01T00:00:002017A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.28819400Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NKJournal of CancerRapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009.J Cancer2017-07-05T00:00:002017Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation.29470805Clifton K, Gutierrez-Barrera A, Ma J, Bassett R, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun BBreast cancer research and treatmentAdjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018 Jul; 170(1):101-109.Breast Cancer Res Treat2018-02-22T00:00:002018Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.29387785Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, Hortobagyi GNNPJ breast cancerCharacterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018; 4:2.NPJ Breast Cancer2018-01-25T00:00:002018Characterization of bone only metastasis patients with respect to tumor subtypes.29439772Chambers MS, Rugo HS, Litton JK, Meiller TFJournal of the American Dental Association (1939)Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast?cancer. J Am Dent Assoc. 2018 04; 149(4):291-298.J Am Dent Assoc2018-02-10T00:00:002018Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast?cancer.29498456Clifton K, Barnett C, Martinez A, Karuturi M, Saleem S, Litton JThe breast journalSevere hyponatremia following cyclophosphamide infusion in breast cancer patients. Breast J. 2018 07; 24(4):691-692.Breast J2018-03-02T00:00:002018Severe hyponatremia following cyclophosphamide infusion in breast cancer patients.29574039Vreeland TJ, Litton JK, Qiao N, Philips AV, Alatrash G, Hale DF, Jackson DO, Peace KM, Greene JM, Berry JS, Clifton GT, Peoples GE, Mittendorf EAClinical immunology (Orlando, Fla.)Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response. Clin Immunol. 2018 07; 192:6-13.Clin Immunol2018-03-21T00:00:002018Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.29733510Elsayegh N, Webster RD, Gutierrez Barrera AM, Lin H, Kuerer HM, Litton JK, Bedrosian I, Arun BKCancer medicineContralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 2018 06; 7(6):2718-2726.Cancer Med2018-05-07T00:00:002018Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.30077429Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NTClinical breast cancerNeoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer. 2018 12; 18(6):e1283-e1288.Clin Breast Cancer2018-07-10T00:00:002018Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.29915946Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NTBreast cancer research and treatmentImpact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018 Sep; 171(2):501-511.Breast Cancer Res Treat2018-06-18T00:00:002018Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.30118680Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MCMolecular cellMetformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell. 2018 08 16; 71(4):606-620.e7.Mol Cell2018-08-16T00:00:002018Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.30110579Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon?alves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roch? H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JLThe New England journal of medicineTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 08 23; 379(8):753-763.N Engl J Med2018-08-15T00:00:002018Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.30025819Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GEClinical immunology (Orlando, Fla.)Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design. Clin Immunol. 2018 10; 195:28-35.Clin Immunol2018-07-17T00:00:002018Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.D011252Disorders1422220.837532Pregnancy Complications, NeoplasticAuthorship 9425652Authorship 942670730817999Clifton GT, Peace KM, Holmes JP, Vreeland TJ, Hale DF, Herbert GS, Litton JK, Murthy RK, Lukas J, Peoples GE, Mittendorf Elizabeth AClinical immunology (Orlando, Fla.)Initial safety analysis of a randomized phase II trial of nelipepimut-S?+?GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. Clin Immunol. 2019 04; 201:48-54.Clin Immunol2019-02-25T00:00:002019Initial safety analysis of a randomized phase II trial of nelipepimut-S?+?GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.30789866Garber HR, Litton JKCurrent opinion in oncologyIntegrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. Curr Opin Oncol. 2019 05; 31(3):247-255.Curr Opin Oncol2019-05-01T00:00:002019Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.Authorship 94381411Authorship 944150830120166Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GNThe oncologistPrognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. Oncologist. 2018 11; 23(11):1282-1288.Oncologist2018-08-17T00:00:002018Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases.30139837Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, Janku F, Moulder SLThe oncologistComparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.Oncologist2018-08-23T00:00:002018Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.Authorship 9450191530973611Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EAJAMA oncologyCurrent Landscape of Immunotherapy in Breast Cancer: A Review. JAMA Oncol. 2019 Aug 01; 5(8):1205-1214.JAMA Oncol2019-08-01T00:00:002019Current Landscape of Immunotherapy in Breast Cancer: A Review.D064726Disorders31811970.485715Triple Negative Breast Neoplasms23909068Woodard TL, Litton JKOncology (Williston Park, N.Y.)Fertility preservation in women with breast cancer: challenges and opportunities. Oncology (Williston Park). 2013 Jun; 27(6):544, 546.Oncology (Williston Park)2013-06-01T00:00:002013Fertility preservation in women with breast cancer: challenges and opportunities.Authorship 946980131099622Litton JK, Burstein HJ, Turner NCAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingMolecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e1-e7.Am Soc Clin Oncol Educ Book2019-05-17T00:00:002019Molecular Testing in Breast Cancer.Authorship 950483431231679Sinn BV, Fu C, Lau R, Litton J, Tsai TH, Murthy R, Tam A, Andreopoulou E, Gong Y, Murthy R, Gould R, Zhang Y, King TA, Viale A, Andrade V, Giri D, Salgado R, Laios I, Sotiriou C, Marginean EC, Kwiatkowski DN, Layman RM, Booser D, Hatzis C, Vicente Valero V, Fraser Symmans WNPJ breast cancerSETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. NPJ Breast Cancer. 2019; 5:16.NPJ Breast Cancer2019-05-30T00:00:002019SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer.Authorship 9511931031277699Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam FBreast cancer research : BCRPhase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.Breast Cancer Res2019-07-05T00:00:002019Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.Authorship 9532991231381960Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, Bernstein JL, Evans JD, Gerber NK, Kerns SL, Keen J, Litton JK, Reiner AS, Riaz N, Rosenstein BS, Sawakuchi GO, Shaitelman SF, Powell SN, Woodward WAInternational journal of radiation oncology, biology, physicsThe Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):698-712.Int J Radiat Oncol Biol Phys2019-08-02T00:00:002019The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists.Authorship 954601131461380Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BKJournal of clinical oncology : official journal of the American Society of Clinical OncologyNeoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.J Clin Oncol2019-08-28T00:00:002019Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.Authorship 955973931552380Daniels M, Wathoo C, Brusco L, Lu KH, Shaw K, Dumbrava EEI, Arun B, Strong L, Litton JK, Eterovic K, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam FJCO precision oncologyActive Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precis Oncol. 2017; 1.JCO Precis Oncol2017-10-31T00:00:002017Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes.Authorship 9570281431602395Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams SNPJ breast cancerTwo may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. NPJ Breast Cancer. 2019; 5:34.NPJ Breast Cancer2019-10-08T00:00:002019Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.Authorship 962507531831881Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, Klugman S, Esplin ED, Jarvik GP, Professional Practice and Guidelines
CommitteeGenetics in medicine : official journal of the American College of Medical GeneticsPoints to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020 04; 22(4):681-685.Genet Med2019-12-13T00:00:002019Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG).Authorship 978369532071118Clifton GT, Hale D, Vreeland TJ, Hickerson AT, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips AV, Lukas JJ, Holmes JP, Peoples GE, Mittendorf EAClinical cancer research : an official journal of the American Association for Cancer ResearchResults of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2515-2523.Clin Cancer Res2020-02-18T00:00:002020Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.Authorship 97910715Authorship 9794941732195033Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MCAmerican journal of cancer researchBlocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res. 2020; 10(2):648-661.Am J Cancer Res2020-02-01T00:00:002020Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.32162822Hurvitz SA, Gon?alves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl JThe oncologistTalazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 03; 25(3):e439-e450.Oncologist2019-11-25T00:00:002019Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.Authorship 980059532211581Emborgo TS, Saporito D, Muse KI, Barrera AMG, Litton JK, Lu KH, Arun BKJNCI cancer spectrumProspective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa002.JNCI Cancer Spectr2020-01-20T00:00:002020Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer.Authorship 9863761332243226Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik DJournal of clinical oncology : official journal of the American Society of Clinical OncologyManagement of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020 06 20; 38(18):2080-2106.J Clin Oncol2020-04-03T00:00:002020Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.Authorship 9866611832259785Daly MB, Pilarski R, Yurgelun MB, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Garber JE, Goggins M, Hutton ML, Khan S, Klein C, Kohlmann W, Kurian AW, Laronga C, Litton JK, Mak JS, Menendez CS, Merajver SD, Norquist BS, Offit K, Pal T, Pederson HJ, Reiser G, Shannon KM, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Dwyer MA, Darlow SDJournal of the National Comprehensive Cancer Network : JNCCNNCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. J Natl Compr Canc Netw. 2020 04; 18(4):380-391.J Natl Compr Canc Netw2020-04-01T00:00:002020NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.Authorship 9878801132323103Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GEBreast cancer research and treatmentProspective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020 Jun; 181(2):391-401.Breast Cancer Res Treat2020-04-22T00:00:002020Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.Authorship 9881361532337496Rugo HS, Ettl J, Hurvitz SA, Gon?alves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann WJNCI cancer spectrumOutcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4(1):pkz085.JNCI Cancer Spectr2019-10-21T00:00:002019Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy.Authorship 9904463Authorship 990457332468579Yu Y, Elmeliegy M, Litton JK, Tudor IC, Czibere A, Zheng J, Wang DDJournal of clinical pharmacologyTalazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial. J Clin Pharmacol. 2020 10; 60(10):1324-1333.J Clin Pharmacol2020-05-28T00:00:002020Talazoparib Exposure-Efficacy Analysis in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA Trial.32468645Elmeliegy M, Yu Y, Litton JK, Czibere A, Wilson GG, Tudor IC, Zheng J, Wang DDJournal of clinical pharmacologyExposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials. J Clin Pharmacol. 2020 10; 60(10):1334-1343.J Clin Pharmacol2020-05-28T00:00:002020Exposure-Safety Analyses of Talazoparib in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations in the EMBRACA and ABRAZO Trials.Authorship 997849132828825Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gon?alves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roch? H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl JAnnals of oncology : official journal of the European Society for Medical OncologyTalazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 11; 31(11):1526-1535.Ann Oncol2020-08-20T00:00:002020Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.Authorship 9994571932920733Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, Mahmoud HS, White JB, Ravenberg EE, Litton JK, Valero V, Wei P, Thompson AM, Moulder SL, Pagel MD, Ma J, Yang WT, Rauch GMBreast cancer research and treatmentTumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.Breast Cancer Res Treat2020-09-13T00:00:002020Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).Authorship 10009841132984932Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SLInvestigational new drugsA phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs. 2021 04; 39(2):509-515.Invest New Drugs2020-09-28T00:00:002020A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.Authorship 10083301933406487Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, CGC, Karlan BY, Khan S, Klein C, Kohlmann W, CGC, Kurian AW, Laronga C, Litton JK, Mak JS, LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, CGC, Senter-Jamieson L, CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MAJournal of the National Comprehensive Cancer Network : JNCCNGenetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 01 06; 19(1):77-102.J Natl Compr Canc Netw2021-01-06T00:00:002021Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.Authorship 1009808833485895Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Kemp Bohan PM, McCarthy PM, Litton JK, Alatrash G, Murthy RK, Qiao N, Philips A, Lukas J, Holmes JP, Mittendorf EA, Peoples GEClinical immunology (Orlando, Fla.)Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol. 2021 04; 225:108679.Clin Immunol2021-01-22T00:00:002021Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer.Authorship 10115542133586845Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma JJournal of magnetic resonance imaging : JMRIFunctional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2021 07; 54(1):251-260.J Magn Reson Imaging2021-02-15T00:00:002021Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.Authorship 1016686833878210Adrada BE, Candelaria R, Moulder S, Thompson A, Wei P, Whitman GJ, Valero V, Litton JK, Santiago L, Scoggins ME, Moseley TW, White JB, Ravenberg EE, Yang WT, Rauch GMCancerEarly ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.Cancer2021-04-20T00:00:002021Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.Authorship 102494024Authorship 10252671734253579Yam C, Yen EY, Chang JT, Bassett RL, Alatrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra Cuentas ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder SL, Mittendorf EAClinical cancer research : an official journal of the American Association for Cancer ResearchImmune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.Clin Cancer Res2021-10-01T00:00:002021Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.34272161Candelaria RP, Spak DA, Rauch GM, Huo L, Bassett RL, Santiago L, Scoggins ME, Guirguis MS, Patel MM, Whitman GJ, Moulder SL, Thompson AM, Ravenberg EE, White JB, Abuhadra NK, Valero V, Litton J, Adrada BE, Yang WTAcademic radiologyBI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.Acad Radiol2021-07-14T00:00:002021BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.Authorship 10261962Authorship 1026435934309473Hobbs EA, Litton JK, Yap TAExpert opinion on pharmacotherapyDevelopment of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother. 2021 Oct; 22(14):1825-1837.Expert Opin Pharmacother2021-07-26T00:00:002021Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.34324367Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HSJournal of clinical oncology : official journal of the American Society of Clinical OncologyEndocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3959-3977.J Clin Oncol2021-07-29T00:00:002021Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.Authorship 10276771734389617Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, Kalinsky K, McArthur HL, Mittendorf EA, Nanda R, Page DB, Rugo HS, Rubin KM, Soliman H, Spears PA, Tolaney SM, Litton JKJournal for immunotherapy of cancerSociety for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021 08; 9(8).J Immunother Cancer2021-08-01T00:00:002021Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.Authorship 1029684334518313Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GBClinical cancer research : an official journal of the American Association for Cancer ResearchPhase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res. 2021 12 01; 27(23):6354-6365.Clin Cancer Res2021-09-13T00:00:002021Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.Authorship 103070411Authorship 10310711134582940Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SFInternational journal of radiation oncology, biology, physicsBreast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):437-444.Int J Radiat Oncol Biol Phys2021-09-25T00:00:002021Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing.34610390Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SFInternational journal of radiation oncology, biology, physicsOutcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation. Int J Radiat Oncol Biol Phys. 2022 02 01; 112(2):426-436.Int J Radiat Oncol Biol Phys2021-10-03T00:00:002021Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation.Authorship 10342041034782633Kai M, Marx AN, Liu DD, Shen Y, Gao H, Reuben JM, Whitman G, Krishnamurthy S, Ross MI, Litton JK, Lim B, Ibrahim N, Kogawa T, Ueno NTScientific reportsA phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. Sci Rep. 2021 11 15; 11(1):22242.Sci Rep2021-11-15T00:00:002021A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer.Authorship 10345601934839351Sun X, Zhai J, Sun B, Parra ER, Jiang M, Ma W, Wang J, Kang AM, Kannan K, Pandurengan R, Zhang S, Solis LM, Haymaker CL, Raso MG, Mendoza Perez J, Sahin AA, Wistuba II, Yam C, Litton JK, Yang FModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncEffector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Mod Pathol. 2022 05; 35(5):601-608.Mod Pathol2021-11-27T00:00:002021Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.Authorship 10381113Authorship 10390883Authorship 1040927635193025Jimenez JE, Abdelhafez A, Mittendorf EA, Elshafeey N, Yung JP, Litton JK, Adrada BE, Candelaria RP, White J, Thompson AM, Huo L, Wei P, Tripathy D, Valero V, Yam C, Hazle JD, Moulder SL, Yang WT, Rauch GMEuropean journal of radiologyA model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.Eur J Radiol2022-02-15T00:00:002022A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer.35091441Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roch? HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LAClinical cancer research : an official journal of the American Association for Cancer ResearchDeterminants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer. Clin Cancer Res. 2022 04 01; 28(7):1383-1390.Clin Cancer Res2022-04-01T00:00:002022Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.35267631Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo LCancersPrognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).Cancers (Basel)2022-03-04T00:00:002022Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer.Authorship 104492918Authorship 10450561335499264Musall BC, Adrada BE, Candelaria RP, Mohamed RMM, Abdelhafez AH, Son JB, Sun J, Santiago L, Whitman GJ, Moseley TW, Scoggins ME, Mahmoud HS, White JB, Hwang KP, Elshafeey NA, Boge M, Zhang S, Litton JK, Valero V, Tripathy D, Thompson AM, Yam C, Wei P, Moulder SL, Pagel MD, Yang WT, Ma J, Rauch GMJournal of magnetic resonance imaging : JMRIQuantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.J Magn Reson Imaging2022-05-02T00:00:002022Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.35507014Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JTClinical cancer research : an official journal of the American Association for Cancer ResearchMolecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.Clin Cancer Res2022-07-01T00:00:002022Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.Authorship 10457651335538088Liu X, Ge Z, Yang F, Contreras A, Lee S, White JB, Lu Y, Labrie M, Arun BK, Moulder SL, Mills GB, Piwnica-Worms H, Litton JK, Chang JTNPJ breast cancerIdentification of biomarkers of response to preoperative talazoparib monotherapy in treatment na?ve gBRCA+ breast cancers. NPJ Breast Cancer. 2022 May 10; 8(1):64.NPJ Breast Cancer2022-05-10T00:00:002022Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment na?ve gBRCA+ breast cancers.Authorship 10487941535736816Kumar T, Hobbs E, Yang F, Chang JT, Contreras A, Cuentas ERP, Garber H, Lee S, Lu Y, Scoggins ME, Adrada BE, Whitman GJ, Arun BK, Mittendorf EA, Litton JKClinical cancer research : an official journal of the American Association for Cancer ResearchTumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation. Clin Cancer Res. 2022 09 01; 28(17):3669-3676.Clin Cancer Res2022-09-01T00:00:002022Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.Authorship 106279113Authorship 105869910Authorship 10566291836670144Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma JScientific reportsPrediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.Sci Rep2023-01-20T00:00:002023Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI.35914239Wu C, Jarrett AM, Zhou Z, Elshafeey N, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Huo L, White JB, Tripathy D, Valero V, Litton JK, Yam C, Son JB, Ma J, Rauch GM, Yankeelov TECancer researchMRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Res. 2022 Sep 16; 82(18):3394-3404.Cancer Res2022-09-16T00:00:002022MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.36034598Irajizad E, Wu R, Vykoukal J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenberg E, Lim B, Litton J, Tripathym D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R, White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JFFrontiers in artificial intelligenceApplication of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Front Artif Intell. 2022; 5:876100.Front Artif Intell2022-08-11T00:00:002022Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Authorship 10645381536831368Panthi B, Adrada BE, Candelaria RP, Guirguis MS, Yam C, Boge M, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Mohamed RM, Musall BC, Pashapoor S, Patel MM, Perez F, Son JB, Thompson A, Valero V, Wei P, White J, Xu Z, Pinsky L, Tripathy D, Yang W, Ma J, Rauch GMCancersAssessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI. Cancers (Basel). 2023 Feb 06; 15(4).Cancers (Basel)2023-02-06T00:00:002023Assessment of Response to Neoadjuvant Systemic Treatment in Triple-Negative Breast Cancer Using Functional Tumor Volumes from Longitudinal Dynamic Contrast-Enhanced MRI.Authorship 1065650936927527Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JVJournal for immunotherapy of cancerFirst-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1). J Immunother Cancer. 2023 03; 11(3).J Immunother Cancer2023-03-01T00:00:002023First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).Authorship 106767525Authorship 10687992037061619Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JKBreast cancer research and treatmentA phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.Breast Cancer Res Treat2023-04-15T00:00:002023A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer.37043123Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam CInvestigational new drugsTargeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.Invest New Drugs2023-04-12T00:00:002023Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.Authorship 107315627Authorship 10726761Authorship 1072119137433103Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, Amiri-Kordestani L, Basho RK, Best AF, Boileau JF, Denkert C, Foster JC, Harbeck N, Jacene HA, King TA, Mason G, O'Sullivan CC, Prowell TM, Richardson AL, Sepulveda KA, Smith ML, Tjoe JA, Turashvili G, Woodward WA, Butler LP, Schwartz EI, Korde LAJournal of clinical oncology : official journal of the American Society of Clinical OncologyStandardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023 09 20; 41(27):4433-4442.J Clin Oncol2023-07-11T00:00:002023Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.37318349Litton JK, Beck JT, Jones JM, Andersen J, Blum JL, Mina LA, Brig R, Danso M, Yuan Y, Abbattista A, Noonan K, Niyazov A, Chakrabarti J, Czibere A, Symmans WF, Telli MLThe oncologistNeoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. Oncologist. 2023 10 03; 28(10):845-855.Oncologist2023-10-03T00:00:002023Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.37444385Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo LCancersPredictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).Cancers (Basel)2023-06-21T00:00:002023Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial.Authorship 10755361937505106Hwang KP, Elshafeey NA, Kotrotsou A, Chen H, Son JB, Boge M, Mohamed RM, Abdelhafez AH, Adrada BE, Panthi B, Sun J, Musall BC, Zhang S, Candelaria RP, White JB, Ravenberg EE, Tripathy D, Yam C, Litton JK, Huo L, Thompson AM, Wei P, Yang WT, Pagel MD, Ma J, Rauch GMRadiology. Imaging cancerA Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer. Radiol Imaging Cancer. 2023 07; 5(4):e230009.Radiol Imaging Cancer2023-07-01T00:00:002023A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.Authorship 1079281637547448Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo LTherapeutic advances in medical oncologyPTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.Ther Adv Med Oncol2023-08-02T00:00:002023PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.Authorship 1080259837795002Akkoc Mustafayev FN, Liu DD, Gutierrez AM, Lewis JE, Ibrahim NK, Valero V, Booser DJ, Litton JK, Koenig K, Yu D, Sneige N, Arun BKEuropean journal of breast healthShort-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. Eur J Breast Health. 2023 Oct; 19(4):267-273.Eur J Breast Health2023-10-01T00:00:002023Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention.Authorship 10809362637835523Xu Z, Rauch DE, Mohamed RM, Pashapoor S, Zhou Z, Panthi B, Son JB, Hwang KP, Musall BC, Adrada BE, Candelaria RP, Leung JWT, Le-Petross HTC, Lane DL, Perez F, White J, Clayborn A, Reed B, Chen H, Sun J, Wei P, Thompson A, Korkut A, Huo L, Hunt KK, Litton JK, Valero V, Tripathy D, Yang W, Yam C, Ma JCancersDeep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer. Cancers (Basel). 2023 Oct 02; 15(19).Cancers (Basel)2023-10-02T00:00:002023Deep Learning for Fully Automatic Tumor Segmentation on Serially Acquired Dynamic Contrast-Enhanced MRI Images of Triple-Negative Breast Cancer.Authorship 10831121437941561Panthi B, Mohamed RM, Adrada BE, Boge M, Candelaria RP, Chen H, Hunt KK, Huo L, Hwang KP, Korkut A, Lane DL, Le-Petross HC, Leung JWT, Litton JK, Pashapoor S, Perez F, Son JB, Sun J, Thompson A, Tripathy D, Valero V, Wei P, White J, Xu Z, Yang W, Zhou Z, Yam C, Rauch GM, Ma JFrontiers in oncologyLongitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer. Front Oncol. 2023; 13:1264259.Front Oncol2023-10-24T00:00:002023Longitudinal dynamic contrast-enhanced MRI radiomic models for early prediction of response to neoadjuvant systemic therapy in triple-negative breast cancer.Authorship 10853011838083160Zhou Z, Adrada BE, Candelaria RP, Elshafeey NA, Boge M, Mohamed RM, Pashapoor S, Sun J, Xu Z, Panthi B, Son JB, Guirguis MS, Patel MM, Whitman GJ, Moseley TW, Scoggins ME, White JB, Litton JK, Valero V, Hunt KK, Tripathy D, Yang W, Wei P, Yam C, Pagel MD, Rauch GM, Ma JAnnual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International ConferencePredicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs. Annu Int Conf IEEE Eng Med Biol Soc. 2023 07; 2023:1-4.Annu Int Conf IEEE Eng Med Biol Soc2023-07-01T00:00:002023Predicting pathological complete response to neoadjuvant systemic therapy for triple-negative breast cancers using deep learning on multiparametric MRIs.Authorship 10881611338294179Musall BC, Rauch DE, Mohamed RMM, Panthi B, Boge M, Candelaria RP, Chen H, Guirguis MS, Hunt KK, Huo L, Hwang KP, Korkut A, Litton JK, Moseley TW, Pashapoor S, Patel MM, Reed BJ, Scoggins ME, Son JB, Tripathy D, Valero V, Wei P, White JB, Whitman GJ, Xu Z, Yang WT, Yam C, Adrada BE, Ma JJournal of magnetic resonance imaging : JMRIDiffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy. J Magn Reson Imaging. 2024 Jan 31.J Magn Reson Imaging2024-01-31T00:00:002024Diffusion Tensor Imaging for Characterizing Changes in Triple-Negative Breast Cancer During Neoadjuvant Systemic Therapy.38484209Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran SJCO precision oncologyComprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes. JCO Precis Oncol. 2024 Mar; 8:e2300124.JCO Precis Oncol2024-03-01T00:00:002024Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.Authorship 10908328Authorship 10909031238502947Garber HR, Basu S, Jindal S, He Z, Chu K, Raghavendra AS, Yam C, Santiago L, Adrada BE, Sharma P, Mittendorf EA, Litton JKOncotargetDurvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 2024 Mar 19; 15:238-247.Oncotarget2024-03-19T00:00:002024Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professortrue1InstructorInstructortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor24072553Rich TA, Liu M, Etzel CJ, Bannon SA, Mork ME, Ready K, Saraiya DS, Grubbs EG, Perrier ND, Lu KH, Arun BK, Woodard TL, Schover LR, Litton JKFamilial cancerComparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes. Fam Cancer. 2014 Jun; 13(2):291-9.Fam Cancer2014-06-01T00:00:002014Comparison of attitudes regarding preimplantation genetic diagnosis among patients with hereditary cancer syndromes.24951607Woodson AH, Muse KI, Lin H, Jackson M, Mattair DN, Schover L, Woodard T, McKenzie L, Theriault RL, Hortob?gyi GN, Arun B, Peterson SK, Profato J, Litton JKThe oncologistBreast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. Oncologist. 2014 Aug; 19(8):797-804.Oncologist2014-06-20T00:00:002014Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis.